Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Enjoy this offer
* See conditions under "Our services"

Valuation: Abivax

Capitalization 7.1B 8.2B 6.54B 6.14B 11.43B 785B 11.63B 77.24B 30.12B 378B 30.78B 30.1B 1,313B P/E ratio 2026 *
-23.2x
P/E ratio 2027 * -25.7x
Enterprise value 6.62B 7.64B 6.09B 5.72B 10.65B 731B 10.83B 71.98B 28.06B 353B 28.68B 28.05B 1,224B EV / Sales 2026 *
1,764x
EV / Sales 2027 * 73.5x
Free-Float
93.56%
Yield 2026 *
-
Yield 2027 * -
1 day+1.48%
1 week-20.26%
Current month-21.38%
1 month-15.50%
3 months-5.16%
6 months-10.76%
Current year-25.96%
1 week 60.45
Extreme 60.45
93.35
1 month 60.45
Extreme 60.45
118.6
Current year 60.45
Extreme 60.45
132
1 year 5.12
Extreme 5.12
132
3 years 4.51
Extreme 4.51
132
5 years 4.51
Extreme 4.51
132
10 years 3.87
Extreme 3.87
132
Manager TitleAgeSince
Chief Executive Officer 68 2023-05-04
Director of Finance/CFO - 2017-01-01
Chief Tech/Sci/R&D Officer - 2026-03-18
Director TitleAgeSince
Chairman - 2022-08-15
Chairman 68 2023-05-04
Director/Board Member 60 2023-07-10
Date Insider Type Main position Quantity % Market Cap.
05-20Fiscal year

Chief Executive Officer

35,456 0.0445%
03-22Fiscal year

Chief Executive Officer

35,456 0.0448%
02-19Free

Director

2,471 0.0032%
Change 5d. change 1-year change 3-years change Capi.($)
+1.48%-20.26%+1,111.28%+457.19% 8.08B
+0.76%-1.39%-14.67%-15.35% 42.68B
-0.50%-9.28%+261.38%+497.79% 31.73B
+0.13%-1.68%+20.59%-10.91% 30.62B
+0.26%-3.18%+5.84%+24.76% 30.03B
-7.00%-12.69%+6.72%+8.66% 24.25B
-0.06%+4.88%+11.17%+5.60% 13.17B
-2.20%-5.95% - - 13.07B
+0.80%+1.42%+54.44%+106.55% 12.97B
-1.26%-2.44%+108.39%+76.57% 12.31B
Average -0.76%-4.97%+173.90%+127.87% 21.89B
Weighted average by Cap. -0.75%-4.53%+96.23%+106.16%

Financials

2026 *2027 *
Net sales 3.75M 4.33M 3.45M 3.24M 6.04M 415M 6.14M 40.81M 15.91M 200M 16.26M 15.9M 694M 90.09M 104M 82.9M 77.87M 145M 9.95B 147M 979M 382M 4.8B 390M 382M 16.65B
Net income -267M -308M -246M -231M -429M -29.47B -437M -2.9B -1.13B -14.21B -1.16B -1.13B -49.33B -215M -248M -198M -186M -346M -23.74B -352M -2.34B -911M -11.45B -931M -911M -39.73B
Net Debt -484M -559M -446M -419M -780M -53.5B -793M -5.27B -2.05B -25.8B -2.1B -2.05B -89.55B -483M -557M -444M -417M -777M -53.32B -790M -5.25B -2.05B -25.71B -2.09B -2.05B -89.24B
Logo Abivax
Abivax is a clinical-stage biotechnology company focused on the development of therapeutics that exploit the body's natural regulatory mechanisms to stabilize the immune response in patients suffering from chronic inflammatory diseases. Based in France and the United States, Abivax's lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderate to severe active ulcerative colitis.
Employees
80
Date Price Change Volume
26-06-08 89.15 +1.48% 256,092
26-06-05 87.85 +4.65% 530,615
26-06-04 83.95 +17.82% 706,575
26-06-03 71.25 +12.92% 1,008,671
26-06-02 63.10 -43.56% 1,681,840
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
89.15EUR
Average target price
114.77EUR
Spread / Average Target
+28.74%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ABVX Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
BENEFIT NOW